Women seeking testosterone therapy for menopause symptoms often encounter challenges due to the lack of FDA-approved options in the U.S. As interest grows in treating symptoms such as low sexual desire and fatigue, physicians are faced with insurance rejections and dosing guesswork.
FDA Workshop and Growing Demand
Interest in testosterone therapy is increasing among menopausal women. The FDA recently held a public workshop to evaluate the evidence, safety, and research gaps surrounding testosterone therapy for women during menopause.
Challenges in Prescribing Testosterone
Doctors are limited to off-label prescribing and use compounded formulations due to the absence of FDA-approved products. Dr. Kudzai Dombo, a certified practitioner at Alloy Health, finds that after establishing estrogen and progesterone regimens, many patients inquire about testosterone.
Social media and peer discussions present potential benefits, but the only evidence-backed indication remains hypoactive sexual desire disorder (HSDD). Other claims pertaining to energy, mood, and bone health lack comprehensive clinical support.
Off-Label Workarounds and Coverage Challenges
“Sexual health is part of your entire health,” said Dombo.
Doctors often resort to off-label methods by using compounded creams or micro-dosing male gel packets. This creates hurdles as insurance frequently denies coverage, forcing patients to pay out of pocket or find alternative solutions.
Dombo shared her experience of using male gel packets because the compounded option was more costly. Despite these adaptations, dosing can be tricky, sometimes leading to ineffective results with precise measurement.
Advocacy for Regulatory Action
Advocacy from patients and medical professionals has urged regulatory agencies to examine standardized access to testosterone therapy. Dombo and others believe in continuous advocacy efforts for access.
Regulatory adaptation is expected to provide safer, standardized access to testosterone therapy.
Dombo emphasized the importance of sexual health as a component of overall well-being and remains optimistic about future regulatory changes.